Prostate Cancer Mortality Reduction by Prostate-Specific Antigen-Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)

European Urology

Volumn 56, Issue 4, 2009, Pages 584-591

  Roobol, Monique J ^a   Kerkhof, Melissa ^a   Schröder, Fritz H ^a   Cuzick, Jack ^b   Sasieni, Peter ^b   Hakama, Matti ^c   Stenman, Ulf Hakan ^d   Ciatto, Stefano ^e   Nelen, Vera ^f   Kwiatkowski, Maciej ^g   Lujan, Marcos ^h   Lilja, Hans ^i,j   Zappa, Marco ^e   Denis, Louis ^k   Recker, Franz ^g   Berenguer, Antonio ^h   Ruutu, Mirja ^d   Kujala, Paula ^l   Bangma, Chris H ^a   Aus, Gunnar ^m   Tammela, Teuvo L J ^l   Villers, Arnauld ⁿ   Rebillard, Xavier ^o   Moss, Sue M ^p   de Koning, Harry J ^a   Hugosson, Jonas ^m   Auvinen, Anssi ^q   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c FINNISH CANCER REGISTRY   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e ISPO   (Italy)

^f Provinciaal Instituut voor Hygiene   (Belgium)

^g CANTONAL HOSPITAL AARAU   (Switzerland)

^h HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

ⁱ LUND UNIVERSITY   (Sweden)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k Oncology Centre of Antwerp   (Belgium)

^l TAMPERE UNIVERSITY HOSPITAL   (Finland)

^m SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁿ LILLE UNIVERSITY HOSPITAL   (France)

^o Clinique Beau Soleil   (France)

^p INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^q UNIVERSITY OF TAMPERE   (Finland)

more..

Author keywords

Adjusted analysis; Contamination; Mortality reduction; Non compliance; Prostate cancer; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; STATISTICAL ANALYSIS;

AGED; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 69249209651     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.07.018     Document Type: Article

References (9)

1. Schröder FH, Hugosson J, Roobol MJ, et al. ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 26;360:1320-8.
2. Cuzick J., Edwards R., and Segnan N. Adjusting for non-compliance and contamination in randomized clinical trials. Stat Med 16 (1997) 1017-1029
3. Duffy W., Cuzick J., Tabar L., et al. Correcting for non-compliance bias in case-control studies to evaluate cancer screening programmes. Appl Stat 51 (2002) 235-243
4. Kerkhof M., Roobol M.J., Steyerberg E.W., Cuzick J., and Schröder F.H. Secondary analysis of the European Randomised Study of Screening for Prostate Cancer (ERSPC) - Effect of prostate cancer screening on the development of metastases after adjustment for non-compliance and contamination. J Urol 181 Suppl 1 (2009) 233
5. Roemeling S., Roobol M.J., Otto S.J., et al. Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trial. Prostate 67 (2007) 1053-1060
6. Otto S.J., van der Cruijsen I.W., Liem M.K., et al. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer 105 (2003) 394-399
7. Draisma G., Boer R., Otto S.J., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 (2003) 868-878
8. Ciatto S., Zappa M., Villers A., Paez A., Otto S.J., and Auvinen A. Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening. BJU Int 92 (2003) 97-100
9. Baker S.G., Kramer B.S., and Prorok P.C. Statistical issues in randomized trials of cancer screening. BMC Med Res Methodol 2 (2002) 11